Top

Published in:

18-07-2023 | AdisInsight Report

Fezolinetant: First Approval

Author: Arnold Lee

Published in: Drugs | Issue 12/2023

Abstract

Fezolinetant (VEOZAH™) is an oral, small molecule, neurokinin 3 receptor (NK3R) antagonist, which is being developed by Astellas Pharma Inc. for the treatment of moderate to severe vasomotor symptoms (VMS) or hot flashes due to menopause. Inhibiting NK3R-mediated signalling in the central nervous system is a non-hormonal strategy to modulate the activity of neurones that are associated with thermoregulation, thereby reducing the frequency and severity of VMS. Fezolinetant received its first approval in the USA in May 2023 for the treatment of moderate to severe VMS due to menopause. This article summarizes the milestones in the development of fezolinetant leading to this first approval in this indication.

Available only for authorised users

US Food & Drug Administration. FDA approves novel drug to treat moderate to severe hot flashes caused by menopause [media release]. 12 May 2023. https://www.fda.gov/.

Depypere H, Lademacher C, Siddiqui E, et al. Fezolinetant in the treatment of vasomotor symptoms associated with menopause. Expert Opin Investig Drugs. 2021;30(7):681–94.CrossRefPubMed

Skorupskaite K, Anderson RA. Hypothalamic neurokinin signalling and its application in reproductive medicine. Pharmacol Ther. 2022;230(107960):1–11.

Astellas Pharma US Inc. VEOZAH^TM (fezolinetant): US prescribing information. 2023. https://dailymed.nlm.nih.gov/. Accessed 23 Jun 2023.

Euroscreen SA. Euroscreen initiates phase I clinical trial for ESN364 [media release]. 18 Dec 2013. http://www.euroscreen.com.

Ogeda. New identity reflects Ogeda's successful transition to GPCR drug discovery development [media release]. 19 Oct 2016. http://www.ogeda.com.

Astellas Pharma Inc. Astellas completes acquisition of Ogeda SA [media release]. 16 May 2017. http://www.astellas.com.

Tahara A, Takamatsu H, Ohtake A, et al. Effects of neurokinin 3 receptor antagonist fezolinetant on hot flash-like symptoms in ovariectomized rats. Eur J Pharmacol. 2021;905(174207):1–9.

Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–102.CrossRefPubMed

10.

Johnson KA, Martin N, Nappi RE, et al. Efficacy and safety of fezolinetant in moderate-to-severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab. 2023;108(8):1981–97.CrossRefPubMedPubMedCentral

11.

Astellas Pharma Inc. Astellas announces topline 12-week results from phase 3 study of fezolinetant for the nonhormonal treatment of vasomotor symptoms in women in Asia [media release]. 14 Mar 2022. http://www.astellas.com.

12.

Astellas Pharma Inc. Phase 3b trial of fezolinetant shows positive topline results for treatment of VMS due to menopause [media release]. 27 Jun 2023. https://www.astellas.com/.

13.

Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27(4):382–92.CrossRefPubMedPubMedCentral

14.

Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104(12):5893–905.CrossRefPubMed

15.

Neal-Perry G, Cano A, Lederman S, et al. Safety of fezolinetant for vasomotor symptoms associated with menopause: a randomized controlled trial. Obstet Gynecol. 2023;141(4):737–47.CrossRefPubMedPubMedCentral

Title: Fezolinetant: First Approval
Author: Arnold Lee
Publication date: 18-07-2023
Publisher: Springer International Publishing
Published in: Drugs / Issue 12/2023
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-023-01917-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Fezolinetant: First Approval

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2023

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes

Pharmacologic Management of Cancer-Related Pain in Pregnant Patients

New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma

Efbemalenograstim Alfa: First Approval

Correction to: Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study

Diabetes of the Exocrine Pancreas: Implications for Pharmacological Management